Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 285

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 285
---
; or |

| ● | a fine or forfeit levied   
 against the office holder. |

Under the Companies Law,
exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors
and, with respect to certain office holders or under certain circumstances, also by the shareholders, as described under “Management—Exculpation,
Insurance and Indemnification of Office Holders” above.

Our amended and restated
articles of association to be in effect upon completion of this offering permit us to exculpate, indemnify and insure our office holders
to the fullest extent permitted by the Companies Law and Securities Law. Each of our office holders have entered into an indemnification
agreement exculpating them, to the fullest extent permitted by Israeli law, from liability to us for damages caused to us as a result
of a breach of the duty of care and undertaking to indemnify them to the fullest extent permitted by Israeli law, including with respect
to liabilities resulting from certain acts performed by such office holders in their capacity as an office holder of the Company or our
affiliates. The indemnification is limited both in terms of amount and coverage.

In the opinion of the SEC,
indemnification of directors and office holders for liabilities arising under the Securities Act, however, is against public policy and
therefore unenforceable.

<div align='center'>II-2</div>

Item 7. Recent Sales of Unregistered Securities.

The following list sets forth
information as to all securities we have sold since March 2022, which were not registered under the Securities Act.

Between August 2020 and
February 2021, we entered into several convertible loan agreements for total consideration of $900,000, or the 2020 CLAs. In October
2024, we proposed to the lenders under the 2020 CLAs to increase the principal amount under their respective portion of the 2020 CLA,
up to an additional aggregate amount of $340,000, or the October 2024 Addendum, so that the 2020 CLAs shall bear interest at 8% per annum
until maturity commencing as of July 1, 2024 with respect to non-participating lenders and March 31, 2025 with respect to participating
lenders. In addition, pursuant to the October 2024 Addendum, upon the occurrence of an initial public offering based on a pre money